Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Israel / NCT07893119
Starting soon Not applicable

Effect of Voiding Position (Standing in the Shower vs. Sitting) on Post- Void Residual Urine Volume (PVR) After Removal of Urinary Catheter in Women Following Vaginal Delivery With Epidural Analgesia: A Double- Blind Randomized Controlled Trial

NCT07893119 · tracked via the Priya Life Science Israel tracker
Sponsor
Assuta Ashdod Hospital
Phase
Not applicable
Started
2026-10-20
Last updated
2026-10-23

Condition(s) studied

Postpartum Urinary Retention

Investigational drug(s) / intervention(s)

Standing in the showerSitting on the toilet

Standing in the shower: The woman is assisted to the shower area and instructed to void in a standing position under running warm water.

Sitting on the toilet: he woman is assisted to the toilet and instructed to void in a sitting position.

Study summary

Postpartum urinary retention is a common complication after childbirth, with a higher risk for women who undergo vaginal delivery with epidural analgesia. This study aims to determine whether performing the first void after the removal of an indwelling urinary catheter in a standing position in the shower, compared to sitting on a toilet, helps reduce postpartum urinary retention. The study will include 100 women who had a vaginal delivery with epidural analgesia. Participants will be randomly assigned to either void while standing in the shower (Group A) or sitting on the toilet (Group B). Immediately after this first spontaneous void, the post-void residual urine volume (PVR) will be measured using an ultrasound bladder scan. The study seeks to find out if the standing position facilitates more complete bladder emptying, reduces the need for recatheterization, and decreases perineal pain compared to the sitting position.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Inclusion Criteria:Adult women (≥18 years old) Singleton pregnancy at ≥37+0 weeks Vaginal delivery (spontaneous or instrumental) Epidural analgesia during labor Indwelling urinary catheter placed during labor or immediately postpartum, with planned removal according to standard clinical protocol Ability to stand (with or without minimal assistance) and to void in the standing or sitting position as allocated Ability and willingness to provide informed consent Exclusion Criteria:Previous known voiding dysfunction or neurogenic bladder Known neurological disease affecting bladder function Major urologic or pelvic reconstructive surgery Obstetric anal sphincter injury grade 3-4 when mobility restrictions or special perineal care preclude standing shower voiding Hemodynamic instability or severe obstetric complications (e.g., severe postpartum hemorrhage, eclampsia) precluding mobilization Active urinary tract infection at the time of catheter removal (clinical signs/symptoms or positive urine culture, as per local protocol) Inability or unwillingness to void in the allocated position Refusal or withdrawal of consent

Primary outcome measure(s)

  • Number of participants with Post-Void Residual Volume (PVR) > 150 mL — Immediately after the first void (within a maximum of 6 hours following catheter removal)
    Post-void residual urine volume (PVR) greater than 150 mL, measured by bladder ultrasound (bladder scan) immediately after the first spontaneous void following catheter removal. This cut-off is consistent with definitions of covert postpartum urinary retention.

Trial sites (1)

FacilityCityRegionStatus
ssuta Ashdod Hospital Ashdod Israel

More Assuta Ashdod Hospital trials in Israel

Effect of Voiding Position (Standing in the Shower vs. Sitting) on Post-Void Residual Urine Volume (PVR) After Removal of Urinary Catheter in Women Following Benign Vaginal Gynecologic Surgery Recruiting
Use of Misoprostol in Hysteroscopic Myomectomy Starting soon
Screening for Fibromyalgia Among Patients With Suspected Endometriosis Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07893119 on ClinicalTrials.gov ↗ ← All trials in Israel